We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The... Klotho Neurosciences, Inc. (NASDAQ: KLTO), a biopharmaceutical company specializing in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders. The Company obtained exclusive worldwide rights to platform technologies and knowhow to develop cutting edge protein, gene and cell therapies to treat age-related pathologies such as ALS, Alzheimer's and Parkinson's Disease, multiple sclerosis and rare neurodegenerative diseases. The company's current portfolio consists of its proprietary gene therapy program using DNA and RNA as therapeutics and diagnostics. Other assets include clinical-stage programs involving antibody biologics targeting cancer and autoimmune diseases, and drug delivery via a needle-free dry powder jet autoinjector called Nanoject. Show more
NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a specialty biotechnology company focused on developing cell and gene therapies for amyotrophic lateral...
NEW YORK, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for neurodegenerative and age-related...
NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a leading biotechnology company focused on developing cell and gene therapies for aging and age-related...
NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a U.S.-based biotechnology company pioneering cell and gene therapies for aging and age-related diseases...
NEW YORK, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative...
NEW YORK, Sept. 29, 2024 (GLOBE NEWSWIRE) -- Klotho Neurosciences, Inc. (NASDAQ: KLTO), a cutting-edge biotechnology company focused on developing innovative therapies for neurodegenerative...
NEW YORK, Sept. 17, 2024 (GLOBE NEWSWIRE) -- The Board of ANEW MEDICAL, INC. (NASDAQ: WENA), today announced a name and ticker symbol change to Klotho Neurosciences, Inc. (NASDAQ: KLTO), and has...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0273 | 6.45390070922 | 0.423 | 0.499 | 0.42 | 103539 | 0.4462043 | CS |
4 | 0.1103 | 32.4411764706 | 0.34 | 0.69 | 0.3255 | 1041270 | 0.39785924 | CS |
12 | -0.0747 | -14.2285714286 | 0.525 | 0.88 | 0.26 | 553982 | 0.4555993 | CS |
26 | -0.3526 | -43.9158052061 | 0.8029 | 0.99 | 0.26 | 468192 | 0.46555668 | CS |
52 | -0.3526 | -43.9158052061 | 0.8029 | 0.99 | 0.26 | 468192 | 0.46555668 | CS |
156 | -0.3526 | -43.9158052061 | 0.8029 | 0.99 | 0.26 | 468192 | 0.46555668 | CS |
260 | -0.3526 | -43.9158052061 | 0.8029 | 0.99 | 0.26 | 468192 | 0.46555668 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions